Pacific Edge has pulled in 36.1 million dollars of fresh equity, and in a sign that confidence is flowing back into one of the country’s best known biotech names, far more small investors wanted in than the Dunedin company had room for.
The cancer diagnostics firm, which makes the Cxbladder family of urine tests used to detect and rule out bladder cancer, confirmed on Wednesday that it had completed its capital raise at 17 cents a share. The total splits into a 25.4 million dollar placement to institutions and larger investors and a 10.7 million dollar retail offer aimed at existing shareholders. The retail portion was the standout. Pacific Edge had set out to raise 6 million dollars from its retail base, yet applications poured in worth about 46 million dollars. The board responded by accepting 4.7 million dollars of oversubscriptions, saying in its announcement to the market that the directors had resolved to do so in recognition of retail investor support.
Roughly 62.7 million new shares will be issued, and they are due to begin trading on the NZX on Thursday. Most eligible shareholders will keep their relative slice of the company broadly intact, with allocations scaled back to spread the heavy demand across the register.
For a stock that spent much of the past two years in the wilderness, the rush to take part is a striking change of mood. Pacific Edge built its reputation on Cxbladder, a test that reads genetic markers in a urine sample to tell doctors whether a patient with blood in their urine is likely to have bladder cancer, sparing many of them an invasive look inside the bladder with a camera. The science is genuinely New Zealand made, grown out of the University of Otago, and for a while the United States market looked like the prize that would turn a clever idea into a profitable company.
That story came apart when American health insurer Medicare stopped paying for the tests. The loss of reimbursement gutted the company’s revenue almost overnight and forced a long, painful retreat. Investors who had once valued Pacific Edge in the billions watched the share price collapse to a few cents, and the question stopped being how fast the company could grow and became whether it could survive at all.
The capital raise that has just closed was pitched against that grim backdrop, but it landed in the middle of a genuine turnaround. On 15 May the Medicare administrator Novitas published a draft local coverage determination proposing to pay for urine biomarker testing in patients with microscopic blood in their urine, naming Cxbladder Triage and Cxbladder Triage Plus in supportive terms. The draft policy reaches roughly 20 million Americans aged 65 and over inside the Novitas jurisdiction and is expected to be finalised before the end of this year. From the day it was published the company began submitting claims again for intermediate risk patients, with the newer Triage Plus test priced at 1,328 US dollars each, about 75 percent more than the 760 US dollars the older test used to fetch.
In other words, the lifeline arrived just as the company went to its shareholders for cash, and the timing helps explain why the offer was swamped. Newswire reported last month that Pacific Edge had posted a full year net loss of 35.8 million dollars, with operating revenue cut roughly in half to 11.5 million dollars as the coverage gap bit. Yet the same results pointed to a leaner business. Average monthly cash burn in the second half of the year fell 27.7 percent to 2.4 million dollars a month, down from 3.3 million dollars, as management stripped out cost while it waited for Washington to move.
The freshly raised money buys time and a buffer to chase the opportunity now opening up. Pacific Edge has said the proceeds will support day to day operations, fund the work of locking in and then expanding Medicare coverage, and pay for the commercial push to get more American urologists ordering the tests. With a draft coverage decision in hand and a final ruling expected within months, the company is trying to rebuild test volumes in the United States quickly enough to grow back into the revenue base it lost.
There is risk in all of this. A draft determination is not a final one, and the company has been burned before by the gap between an encouraging signal from Medicare and money actually landing in the bank. The heavy dilution from issuing tens of millions of new shares also weighs on existing holders, even those who topped up. But the willingness of ordinary shareholders to put in seven times more than the company asked for is the clearest vote of confidence Pacific Edge has had from its own register in years.
For New Zealand’s small and often unloved biotech sector, the result is a rare bright note. Home grown science companies that try to crack the American medical market are usually long on promise and short on cash, and Pacific Edge has lived every chapter of that hard road in public. The completed raise does not end the story, but it does give a Dunedin company that nearly ran out of road another genuine shot at proving the idea works as a business and not just in the lab. Full details of the offer and the company’s recent announcements are on the NZX announcements page, and the wider day’s market moves were covered in the interest.co.nz daily NZX update.
What do you make of Pacific Edge’s comeback, and would you back a New Zealand biotech taking on the American health system? Share your thoughts in the comments below.
This article was written by AI, briefed to report the facts, hopefully without some of the bias people bring to the job 🙂
Leave a Reply